文献速递眼底病与葡萄膜炎

玻璃体腔抗VEGF治疗非感染性葡萄膜炎继发炎性脉络膜新生血管

Intravitreal Antivascular Endothelial Growth Factor Treatment for Inflammatory Choroidal Neovascularization in Noninfectious Uveitis.
PubMed 文献 · Am J Ophthalmol · 2021-07-18

这项回顾性非随机临床研究纳入2000年至2016年Moorfields眼科医院166例(204眼)非感染性炎性脉络膜新生血管(CNV)患者,中位随访6.9年。一线抗VEGF治疗眼(55眼)平均注射4.35次,各时间点视力显著改善(除5年访视P=.25),最终BCVA为0.26±0.11 logMAR(20/36),优于其他治疗眼的0.35±0.06 logMAR(20/44)。

要点

  • 一线抗VEGF治疗眼平均注射4.35次,多数时间点视力显著改善。
  • 口服糖皮质激素或抗VEGF注射均显著降低CNV复发风险。
  • 炎性CNV患眼存在视力丧失风险,早期抗VEGF治疗视力结局更佳。

核心结论

  • 非感染性炎性CNV患眼存在视力丧失风险,早期接受抗VEGF注射者视力结局更好且CNV复发风险降低。
  • 口服糖皮质激素可降低既往治疗眼的CNV复发风险。

研究设计与样本

  • 回顾性、非随机临床研究,纳入2000年1月至2016年4月Moorfields眼科医院葡萄膜炎门诊的非感染性炎性CNV患者。
  • 共166例患者(204眼),中位随访6.9年(四分位距2.9-11.7年;1652眼年)。

主要发现

  • CNV诊断时平均BCVA:一线抗VEGF治疗眼为0.38±0.05 logMAR(Snellen等效20/47),其他治疗眼为0.44±0.03 logMAR(20/55),P=.39。
  • 一线抗VEGF治疗眼(n=55)平均注射4.35±0.53次,除5年访视(P=.25)外各时间点视力均显著改善(P<.001)。
  • 其余眼随访期间视力无显著变化(所有P>.05)。
  • 最终访视平均BCVA:一线抗VEGF治疗眼为0.26±0.11 logMAR(20/36),其他治疗眼为0.35±0.06 logMAR(20/44)。

关键数值与推荐

  • 中位随访6.9年(四分位距2.9-11.7年;1652眼年)。
  • 一线抗VEGF治疗眼平均注射4.35±0.53次。
  • CNV平均复发时间186±15.1个月。

临床怎么用

  • 对非感染性炎性CNV患眼,可考虑早期一线抗VEGF注射以改善视力结局并降低复发风险。
  • 口服糖皮质激素可能有助于降低CNV复发风险,尤其对既往已治疗眼。
  • 需长期随访监测CNV复发,因平均复发时间较长。

局限性

  • 回顾性、非随机设计,治疗分组可能存在选择偏倚。
  • 数据来源于单中心临床病历记录。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare visual outcome and recurrence rates of eyes with noninfectious inflammatory choroidal neovascularization (CNV) treated with or without anti-vascular endothelial growth factor (VEGF) injections and immunosuppression. DESIGN: Retrospective, nonrandomized clinical study. METHODS: Participants: Patients with CNV secondary to noninfectious inflammatory causes who attended uveitis clinics at Moorfields Eye Hospital between January 2000 and April 2016. Data were gathered from the clinical notes of all subjects examined in clinic. MAIN OUTCOME MEASURES: change in best-corrected visual acuity (BCVA), mean time to CNV recurrence, moderate vision loss (≤20/50), and severe vision loss (≤20/200). RESULTS: A total of 166 patients (204 eyes) with noninfectious inflammatory CNV were included in this study with a median follow-up of 6.9 years (interquartile range: 2.9-11.7; 1652 eye-years). The mean BCVA at the time of CNV diagnosis was 0.38 ± 0.05 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent 20/47) in the eyes that received the first-line anti-VEGF treatment and 0.44 ± 0.03 logMAR (Snellen equivalent 20/55) in the eyes on other treatment modalities (P = .39). Eyes treated first with anti-VEGF (n = 55) received the mean of 4.35 ± 0.53 injections and showed a statistically significant improvement in vision at all time points (P < .001) except for a 5-year visit (P = .25). The rest of the eyes demonstrated no significant change in vision throughout follow-up (all P > .05). At the final visit, the mean BCVA was 0.26 ± 0.11 logMAR (Snellen equivalent 20/36) in the former and 0.35 ± 0.06 logMAR (Snellen equivalent 20/44) in the latter. The mean time to CNV recurrence was 186 ± 15.1 months, and the risk was significantly reduced by treatment with oral corticosteroids (adjusted hazard ratio = 0.32, confidence interval: 0.17-0.59, P < .001) or anti-VEGF injections (adjusted hazard ratio = 0.31, confidence interval: 0.18-0.52, P < .001). CONCLUSIONS: Eyes that developed inflammatory CNV were at risk of vision loss. Those receiving early anti-VEGF injections achieved a better visual outcome and had a reduced risk of CNV recurrence. Oral corticosteroids also had an effect that reduces the risk of recurrence in eyes previously treated.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Woronkowicz M, Niederer R, Lightman S, et al. Intravitreal Antivascular Endothelial Growth Factor Treatment for Inflammatory Choroidal Neovascularization in Noninfectious Uveitis. Am J Ophthalmol. 2021. PMID: 34289337. doi:10.1016/j.ajo.2021.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。